Clinical trial
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
NCT00002548 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00002548 |
|---|---|
| Title | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma |
| Official title | Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation and 2 more |
| Enrollment | 899 |
| Start date | Jan 1, 1994 |
| Primary completion | Oct 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Aug 11, 2003 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: